Adage Capital Partners’s United Therapeutics UTHR Stock Holding History

Adage Capital Partners’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-50,000	Closed	-$11M	–	943
2023 Q2	$11M	Sell	50,000 -70,000	-58%	-$15.5M	0.02%	556
2023 Q1	$26.9M	Sell	120,000 -87,000	-42%	-$21.4M	0.06%	343
2022 Q4	$57.6M	Sell	207,000 -148,000	-42%	-$37.4M	0.14%	180
2022 Q3	$74.3M	Buy	355,000 +140,000	+65%	+$31.3M	0.18%	126
2022 Q2	$50.7M	Sell	215,000 -85,000	-28%	-$17.3M	0.12%	183
2022 Q1	$53.8M	Sell	300,000 -100,000	-25%	-$19.1M	0.1%	196
2021 Q4	$86.4M	Hold	400,000	–	–	0.16%	143
2021 Q3	$73.8M	Sell	400,000 -100,000	-20%	-$19.7M	0.15%	149
2021 Q2	$89.7M	Buy	500,000 +75,000	+18%	+$14.3M	0.18%	120
2021 Q1	$71.1M	Sell	425,000 -400,000	-48%	-$66.7M	0.15%	162
2020 Q4	$125M	Sell	825,000 -350,000	-30%	-$45.9M	0.27%	80
2020 Q3	$119M	Buy	1,175,000 +75,000	+7%	+$8.23M	0.3%	71
2020 Q2	$133M	Sell	1,100,000 -186,622	-15%	-$21M	0.34%	57
2020 Q1	$122M	Buy	1,286,622 +536,622	+72%	+$51M	0.36%	62
2019 Q4	$66.1M	Buy	750,000 +500,000	+200%	+$44M	0.16%	165
2019 Q3	$19.9M	Buy	250,000 +100,000	+67%	+$8.05M	0.05%	366
2019 Q2	$11.7M	Buy	+150,000	New	+$14M	0.03%	501

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Adage Capital Partners's UTHR Position: Q3 2023 in Review

Adage Capital Partners sold out of United Therapeutics (UTHR) in Q3 2023, closing a stake of 50,000 shares — an estimated $11M sold.

Adage Capital Partners first reported a position in UTHR in Q2 2019 and held it in 17 quarters. The position peaked at $133M in Q2 2020. 508 funds tracked by Wall St. Rank hold UTHR as of Q3 2023.

Adage Capital Partners reported no remaining United Therapeutics position as of Q3 2023 after selling out during the quarter.
Adage Capital Partners sold 50,000 United Therapeutics shares in Q3 2023, an estimated $11M.
Adage Capital Partners first reported a position in United Therapeutics in Q2 2019 and held it in 17 quarters.
Adage Capital Partners's United Therapeutics position peaked at $133M in Q2 2020.
508 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2023.

Based on Adage Capital Partners's 13F filing for Q3 2023, filed 14 Nov 2023.